Introduction
============

Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy (LVH) in the absence of predisposing conditions such as long-standing hypertension or valvular stenosis. It is the most common genetic cardiovascular disorder inherited in an autosomal dominant mode with a prevalence of at least 1:500 ([@B1]). HCM is the most common cause of sudden death in the youth and a major cause of morbidity in adults ([@B2]).

At least 27 genes have been proposed as HCM susceptibility genes ([@B3]). However, genes encoding protein components of the cardiac sarcomere (sarcomere genes) are accounted for the disease in most of HCM families (60--75%) ([@B4]--[@B6]). Up to 2012, more than 800 exonic and intronic disease associated mutations has been reported in sarcomeric genes ([@B7]). Locus and allelic heterogeneity make the direct mutation detection in HCM cases very difficult. In this situation, linkage analysis can be very helpful by determining the causative locus in appropriate families before sequencing the gene for mutation detection.

In this study we proposed a set of 24 polymorphic microsatellite markers flanking 6 sarcomeric genes including beta-myosin heavy chain (*MYH7*), myosin binding protein C (*MYBPC3*), cardiac troponin T (*TNNT2*), cardiac troponin I (*TNNI3*), alpha-tropomyosin (*TPM1*), regulatory myosin light chain (*MYL2*). The polymorphic indices of markers were evaluated in Iranian population. Multiplex PCR and fragment length analysis was set up to reduce time and money expenses. The feasibility of the method was checked in an Iranian HCM family.

Materials and Methods
=====================

Clinical investigations of a family with HCM
--------------------------------------------

A 40 yr old Iranian woman with HCM was referred for genetic counseling to the Department of Medical Genetics at Tehran University of Medical Sciences in 2011. The clinical diagnosis of HCM had been made by the interventricular septal thickness of ≥13 mm, in the absence of other cardiac or systemic causes of LVH. Her available first-degree relatives were invited for clinical evaluation and blood sampling. The proband and her relatives underwent physical examination, 12-lead electrocardiography, transthoracic two-dimensional echocardiography, and Doppler studies in Shahid Rajaei Cardiovascular Medical Center, Tehran, Iran. The clinical diagnosis of HCM in relatives was established based on McKenna criteria ([@B8]). Proband's mother has died 22 years ago at the age of 51. No medical record was available regarding the cause of her death. However, Proband's explanation of her mother's clinical symptoms was consistent with HCM.

Sampling and DNA extraction
---------------------------

Blood samples were collected from all participants. DNA was extracted by phenol-chloroform method according to standard protocol, stored at 4 °C until analysis. Quality and quantity of the extracted DNA were assessed by Nano Drop spectrophotometer (ND-1000) as well as gel electrophoresis.

Sampling for population study
-----------------------------

Fifty unrelated individuals referring to heart clinics of Shahid Rajaei Hospital for unrelated reasons were randomly recruited for the study. Blood sampling and DNA extractions were performed.

Ethical approval
----------------

This study was approved by the research Ethics Committee of Tehran University of Medical Sciences. Informed consent was obtained from all participants.

Marker Selection
----------------

Four microsatellite markers flanking every one of 6 sarcomere genes (*MYH7*, *MYBPC3*, *TNNT2*, *TNNI3*, *TPM1*, and *MYL2*) were selected from Marshfield genetic map (24 markers in total). Order of markers around each gene was defined by integrating information obtained from the Human Genome Sequencing database (NCBI build 37.3) and Marshfield genetic map ([@B9]). Localization of genes and flanking markers is shown in ([Fig. 1](#F1){ref-type="fig"}). The nearest markers flanking upstream and downstream of each gene with mean heterozygosity (MH) more than 70 percent were assigned for the study. Exceptionally, due to the limitations for PCR multiplexing, 3 markers were selected with MH near 70% ([Table 1](#T1){ref-type="table"}). For *MYH7*, two intragenic markers (MYOI and MYOII) were successfully used in repeated gene tracking studies ([@B10], [@B11]). Therefore, these two markers were selected in our study.

![Localization of microsatellite markers flanking sarcomere genes. The sex-averaged genetic distances were shown in centiMorgan from the p telomeric end of the chromosome. Data obtained from Marshfield genetic map](IJPH-45-329-g001){#F1}

###### 

Characteristics of microsatellite markers flanking each sarcomere gene and their primer sequences and modifications. \* MH: Mean Heterozygosity. \*\* SET1; Initial denaturation: 95°C for 3 min, 10 cycles of touch down PCR with denaturation: 95°C for 30 sec, annealing: 65--60°C for 30 sec (decreases 0.5°C per cycle) with no extension step, 20 cycles of normal PCR with denaturation: 95°C for 30 sec, annealing: 60°C for 30 sec with no extension step, final extension: 72°C for 2 min. Final concentration of MgCl2 was 0.3 mM. SET2; PCR program was the same as SET1. Final concentration of MgCl2 was 0.5 mM. S\#; Initial denaturation: 95°C for 3min, 30 cycles of normal PCR with denaturation: 95°C for 30 sec, annealing: 55°C for 30 sec with no extension step, final extension: 72°C for 2 min. Final concentration of mgCl2 was 1.2 mm

  **Gene**     **Marker**   **Forward Primer**          **Reverse Primer**          **MH ^\*^(%)**   **Length (bp)**   **5' Modification**   **Primer Concentration (pmol/μl)**   **PCR Condition^\*\*^**
  ------------ ------------ --------------------------- --------------------------- ---------------- ----------------- --------------------- ------------------------------------ -------------------------
  **MYH7**     MYO 1        CTGCATCTGAGCATATGGGA        CATTCAGACTATGCAGGCTT        66               90--102           FAM                   0.2                                  SET1
               MYO 2        ATGCCATGTCTATCTGTGCC        AACATCCTCTAACCCTACCCC       81               108--132          HEX                   0.2                                  SET1
               D14S990      GTCCACTTGGTCATGGAAAC        AAGTTGCACTGTGACTGGG         85               135--161          NED                   0.2                                  SET1
               D14S972      TTAACGCATAACAGCCAAGA        TCTGACTGCCTCCATGA           74               201--211          HEX                   0.4                                  SET1
  **MYBPC3**   D11S1344     CCCTGAACTTCTGCATTCAC        GCGCCTGGCTTGTACATATA        82               273--293          HEX                   0.2                                  SET1
               D11S4109     CTGGGAGTTAGGAGACCTGG        TTGAAGAGCCCTCACAGAC         85               155--185          FAM                   0.2                                  SET1
               D11S4174     GATTAAATGCCCACTATGTAGC      GATAGCTTTCCCAGATGGTT        73               277--295          NED                   0.2                                  SET1
               D11S2016     TGCGGCATTATTCATAATCA        ATTTTTTTGGATGAAGTAATACTGG   77               281--301          FAM                   0.4                                  SET1
  **TNNT2**    D1S477       CAGTACAGGTCAACCAAGACGTATG   TCTACAAGGGGCCACTCAG         68               216--230          FAM                   0.2                                  SET1
               D1S1723      AACTGTGTCCAGCAGCAACT        TATGTGCCTGTTGTGTGCAT        83               167--181          HEX                   0.2                                  SET1
               D1S2716      GGCTGCCAAGTCCACTG           GGGTCCTAAAGATAGAAAAATGTCC   66               196--206          NED                   0.2                                  SET1
               D1S2615      ACAGCGCCTGGCTATAA           GACAATGTTGTAGTGCCTGG        78               232--243          NED                   0.2                                  SET1
  **TNNI3**    D19S418      ACCAGGCATCCAGTGTTT          CAACTATCCCGCCTTTGT          67               81--93            FAM                   0.2                                  SET2
               D19S891      AAATTCAACAGCCATTATGG        CGTACCCCTTATCTGATGA         76               99--117           NED                   0.5                                  S^\#^
               D19S926      TCTGGTGAGAATTCCTAAGTAGTTC   GGCCTTATGCGTGAGTAGTT        80               95--113           HEX                   0.3                                  SET2
               D19S887      TATCCAATGCCACAGAAAA         AAGGTTTGCTTGTTTGGGT         74               246--262          NED                   0.3                                  SET2
  **TPM1**     D15S987      ACAGTCCTGCCCTTAGAAA         TAGAACGCTGCCCTCAC           74               162--179          HEX                   0.2                                  SET2
               D15S993      AGAAACCCAGGCTGACTT          GCACTGTTGTGGTCTAATCC        82               177--189          NED                   0.2                                  SET2
               D15S974      TCATAGAATCAGCCAGCCA         AGGGTCAGGAATGGGTC           88               115--146          FAM                   0.2                                  SET2
               D15S1020     TGCACAATGGATACTAAACAGC      CGATAGAGCAAGACTGTCTCAA      86               211--231          NED                   0.3                                  SET2
  **MYL2**     D12S84       GCTTACAGTAGGTGCTTAATAAATG   TGTCTCTAGGCTAATGGCTT        84               198--219          HEX                   0.2                                  SET2
               D12S1646     ACCACTCCATTGCTGGC           GCTGGGTAAGAACCTCTGC         72               247--259          FAM                   0.2                                  SET2
               D12S1342     AGTTTGACCCCCCAGA            GCAGAAGATGAGGGCA            83               266--288          HEX                   0.2                                  SET2
               D12S354      GGTGGTTCTGGGTCAGAT          GGTTTCCTAATTTCAAGTCAA       73               187--205          FAM                   0.3                                  SET2

Multiplexing
------------

Selected Markers were assigned in two sets of 12 markers each (SET1 and SET2). Size fractionation of all 12 markers in each group was made possible by capillary electrophoresis using combination of fluorescently labeled primers. Three different fluorophores including FAM, HEX, and NED were used for labeling primers. Markers in SET1 cover three genomic loci containing *MYH7*, *MYBPC3*, and *TNNT2*. Markers in SET2 span the regions containing other 3 genes (*TNNI3*, *TPM1*, and *MYL2*). Possibility of multiplexing of size fractionation by capillary electrophoresis was also considered in selection of suitable markers.

PCR Setup and Fragment length analysis
--------------------------------------

Primer sequences for genotyping of all 24-microsatellite markers were obtained from NCBI UniSTS databank ([@B12]). All Forward primers were labeled at the 5'end by a fluorophores (FAM, HEX, or NED). Detailed information regarding primer sequences, modifications and characteristics of markers is presented in ([Table 1](#T1){ref-type="table"}). PCR conditions were optimized for amplification of all 24 markers separately. Touchdown PCR, reducing cycles and shortening of extension time were used to decrease the stutter fragments of microsatellites.

In addition, multiplexing of PCR reactions were performed by defining appropriate conditions covering 12 markers of SET1 and 11 markers of SET2 ([Table 1](#T1){ref-type="table"}). Multiplexing of PCR for one marker in SET2 (D19S891) was not successful. The PCR product of this marker was mixed with multiplex PCR product of other 11 markers of SET2 before fragment analysis. Fragment length analysis was done for SET1 and SET2 separately. It was performed by using the Applied Biosystems 3130 Genetic Analyzers and Gene Scan® Analysis Software version 3.7. Gene Scan results were analyzed with peak scanner software v1.0 ([Fig. 2](#F2){ref-type="fig"}). Identified genotypes were entered in a databank for statistical analysis.

![(A) GeneScan results of multiplex fragment length analysis of SET1 including 12 markers analyzed with peakscanner software v1.0. Every 4 markers labeled by a fluorophore are shown separately: (B) FAM, (C) HEX, (D) NED. The fragment size was determine by comparison to the GeneScan™ 400HD ROX™ Size Standard, shown on the upper edge of each diagram.SET2 was not shown](IJPH-45-329-g002){#F2}

Statistical analysis
--------------------

Easy LINKAGE plus v5.05 ([@B13]) was used for linkage analysis. Testing for Mendelian errors was performed by using Merlin v1.0.1. Gene Hunter v2.1r5 software was used for haplotyping and multipoint parametric linkage analysis.

Results
=======

Genotyping of all 24 markers was performed for 50 unrelated people. [Table 2](#T2){ref-type="table"} shows characteristics of different alleles for each marker including repeat number and frequency. Selected markers had 5 to 15 alleles.

###### 

Characteristics of different alleles for selected markers including repeat numbers and frequency in 50 unrelated samples. Markers indicated with \* had half-repeat units (alleles with sizes greater than the typical allele size by one base) represented by 0.5 unit

  **MYH7**      **MYBPC3**    **TNNT2**                                                                                                                               
  ------------- ------------- ------------- ------------- ----------------- ------------- ------------- -------------- ------------ -------------- ------------------ -------------
  14 (0.15)     18 (0.01)     12 (0.01)     12 (0.10)     18 (0.12)         11 (0.11)     18 (0.02)     4 (0.01)       12 (0.08)    16 (0.01)      9 (0.24)           14 (0.01)
  15 (0.46)     22 (0.01)     15 (0.07)     13 (0.44)     19 (0.14)         15 (0.01)     19 (0.02)     10 (0.05)      16 (0.13)    17 (0.01)      11 (0.03)          14.5 (0.06)
  16 (0.29)     23 (0.05)     16 (0.07)     14 (0.11)     20 (0.03)         16 (0.02)     20 (0.03)     11 (0.05)      18 (0.60)    18 (0.18)      12 (0.48)          15 (0.02)
  17 (0.09)     24 (0.31)     17 (0.25)     15 (0.21)     21 (0.02)         17 (0.02)     21 (0.21)     12 (0.12)      19 (0.11)    19 (0.05)      13 (0.22)          15.5 (0.31)
  18 (0.01)     25 (0.30)     18 (0.07)     16 (0.13)     22 (0.14)         18 (0.21)     22 (0.41)     13 (0.45)      20 (0.01)    20 (0.32)      14 (0.3)           16 (0.12)
                26 (0.14)     19 (0.16)     17 (0.01)     23 (0.32)         19 (0.14)     23 (0.13)     14 (0.23)      21 (0.05)    21 (0.19)                         16.5 (0.04)
                27 (0.07)     20 (0.19)                   24 (0.15)         20 (0.16)     24 (0.13)     15 (0.06)      23 (0.01)    22 (0.05)                         17 (0.34)
                28 (0.05)     21 (0.13)                   25 (0.03)         21 (0.16)     25 (0.04)     16 (0.03)      24 (0.01)    23 (0.06)                         18 (0.10)
                29 (0.01)     22 (0.04)                   26 (0.02)         22 (0.06)     26 (0.01)                                 24 (0.06)                         
                30 (0.02)     23 (0.01)                   27 (0.03)         23 (0.05)                                               25 (0.03)                         
                31 (0.01)                                                   24 (0.01)                                               26 (0.02)                         
                32 (0.01)                                                   25 (0.01)                                               27 (0.02)                         
                34 (0.01)                                                   26 (0.01)                                                                                 
                                                                            28 (0.03)                                                                                 
  **TNNI3**     **TPM1**      **MYL2**                                                                                                                                
  **D19S418**   **D19S891**   **D19S926**   **D19S887**   **D15S987^\*^**   **D15S993**   **D15S974**   **D15S1020**   **D12S84**   **D12S1646**   **D12S1342^\*^**   **D12S354**
  11 (0.05)     12 (0.18)     12 (0.46)     16 (0.04)     22 (0.30)         17 (0.03)     20 (0.01)     15 (0.02)      16 (0.09)    15 (0.03)      16.5 (0.18)        11 (0.18)
  12 (0.06)     13 (0.03)     14 (0.03)     17 (0.01)     23 (0.13)         18 (0.05)     21 (0.02)     16 (0.02)      17 (0.06)    16 (0.14)      17.5 (0.15)        13 (0.31)
  13 (0.39)     14 (0.06)     15 (0.21)     18 (0.07)     23.5 (0.05)       19 (0.15)     22 (0.12)     18 (0.17)      18 (0.05)    17 (0.10)      18 (0.01)          14 (0.08)
  14 (0.27)     15 (0.12)     16 (0.09)     19 (0.24)     24 (0.24)         20 (0.27)     23 (0.03)     19 (0.20)      20 (0.01)    18 (0.28)      18.5 (0.24)        16 (0.36)
  15 (0.11)     16 (0.06)     17 (0.06)     20 (0.40)     24.5 (0.25)       21 (0.18)     24 (0.06)     20 (0.15)      21 (0.10)    19 (0.15)      19.5(0.05)         17 (0.05)
  16 (0.10)     17 (0.12)     18 (0.09)     21 (0.19)     25 (0.03)         22 (0.23)     25 (0.04)     21 (0.12)      22 (0.17)    20 (0.25)      20 (0.01)          18 (0.01)
  17 (0.02)     18 (0.09)     19 (0.06)     22 (0.03)                       23 (0.08)     26 (0.05)     22 (0.22)      23 (0.28)    21 (0.05)      20.5 (0.04)        21 (0.01)
                19 (0.27)                   23 (0.02)                       24 (0.01)     27 (0.05)     23 (0.07)      24 (0.14)                   21 (0.21)          
                20 (0.07)                                                                 28 (0.03)     24 (0.03)      25 (0.05)                   21.5 (0.06)        
                                                                                          29 (0.08)                    26 (0.04)                   22 (0.05)          
                                                                                          30 (0.29)                    27 (0.01)                                      
                                                                                          31 (0.13)                                                                   
                                                                                          32 (0.05)                                                                   
                                                                                          33 (0.03)                                                                   
                                                                                          34 (0.01)                                                                   

Mean heterozygosity (MH) and polymorphic information content (PIC) of each marker are presented in [Table 3](#T3){ref-type="table"}. All markers showed PIC above 50%. Mean heterozygosity was above 70% in majority of markers. Only three markers had a mean heterozygosity of 60--70%.

###### 

Mean heterozygosity (MH) and polymorphic information content (PIC) of selected markers in 50 unrelated samples

  **Gene**   **Marker**   **MH (%)**   **PIC**
  ---------- ------------ ------------ ---------
  MYH7       MYO 1        67           0.61
             MYO 2        78           0.75
             D14S990      84           0.82
             D14S972      72           0.68
  MYBPC3     D11S1344     81           0.80
             D11S4109     86           0.85
             D11S4174     75           0.71
             D11S2016     72           0.68
  TNNT2      D1S477       60           0.57
             D1S1723      79           0.79
             D1S2716      66           0.60
             D1S2615      75           0.72
  TNNI3      D19S418      74           0.71
             D19S891      84           0.82
             D19S926      72           0.68
             D19S887      73           0.70
  TPM1       D15S987      77           0.73
             D15S993      81           0.78
             D15S974      86           0.85
             D15S1020     84           0.81
  MYL2       D12S84       84           0.82
             D12S1646     80           0.77
             D12S1342     83           0.81
             D12S354      73           0.68

[Table 4](#T4){ref-type="table"} shows the frequency of combined markers heterozygosity in the panel of markers used around each gene locus. The panel of markers around each locus was considered informative in each sample if at least one of 4 markers was heterozygous. Having this, *MYBPC3*, *TNNI3*, and *MYL2* panels showed 100% informativeness (informative in all 50 evaluated samples). *MYH7*, *TNNT2*, and *TPM1* panels were informative in 96%, 98%, and 98% of samples respectively. Over 70% of cases were heterozygous for 3 to 4 markers flanking each gene.

###### 

Frequency of combined markers heterozygosity in the panel of markers used around each sarcomere gene

                            **Proportion of individuals showing combined markers heterozygosity in markers panel related to each gene**                       
  ------------------------- ------------------------------------------------------------------------------------------------------------- ---- ---- ---- ---- ----
  4-marker heterozygosity   38                                                                                                            32   20   30   32   28
  3-marker heterozygosity   36                                                                                                            40   54   44   44   43
  2-marker heterozygosity   20                                                                                                            26   12   18   18   18
  1-marker heterozygosity   2                                                                                                             2    12   8    4    11
  No heterozygote marker    4                                                                                                             0    2    0    2    0

Case study
----------

Nine members of proband's family were evaluated. In addition to the proband herself, three other members of pedigree were diagnosed with HCM. Simulation of 1000 replicates by Slink resulted in a maximum expected two-point LOD score of 2.10 at θ=0.00 (average=1.33±0.83 standard deviation).

Haplotype analysis for the six genes under study was performed. Marker D12S1646 was removed from the analysis due to the observed Mendelian error, possibly caused by genotyping error. The structure of haplotypes in each locus is shown in ([Fig. 3](#F3){ref-type="fig"}).

![The structure of selected markers haplotypes flanking each sarcomere gene in a family with HCM. The proband indicated with an arrow. Cross-overs are shown by "x". The sex-averaged genetic distance of each marker in centiMorgans (cM) from p telomere of chromosomes is noted](IJPH-45-329-g003){#F3}

Multipoint linkage analysis excluded the linkage between the disease and all six genes by obtaining maximum LOD score ≤−2 ([Fig. 4](#F4){ref-type="fig"}). The analysis was performed under the assumption that the proband's mother had HCM, although her diagnosis cannot be confirmed due to lack of medical documents. Therefore, analysis was repeated by assigning unknown status for her. Again, multipoint linkage analysis showed negative LOD score, suggesting linkage exclusion in all 6 genes.

![The LOD plot of Multipoint linkage analysis between the disease and six sarcomere genes. The relative localization of each marker and the genetic distance between them are shown on X axis in centiMorgans (cM)](IJPH-45-329-g004){#F4}

Discussion
==========

Profound locus and allele heterogeneity, large sarcomere genes with numerous exons and intronic disease causing mutations make the direct mutation detection for HCM time and money consuming. Though new methods such as next generation sequencing/ exome sequencing are helpful ([@B14]--[@B16]), they are demanding in terms of cost, equipment, and expertise. Such methods are available just in few countries around the world. Therefore applying alternative methods for HCM genetic analysis is a necessity in many countries.

Tracking mutated genes by using surrounding DNA markers through linkage analysis is valuable for familial HCM, especially for predictive and screening purposes. Linkage analysis can also be used as the first step in mutation detection. It can reduce the number of candidate genes for direct sequencing through exclusion mapping. In addition, it can identify the most likely disease gene even in families with small size.

We proposed panels of microsatellite markers flanking 6 genes which cause 60 to 75% of familial HCM. Our study showed marker characteristics in Iranian population not studied before. All of 24 markers were highly polymorphic (mean heterozygosity more than 70% except 3 markers with mean heterozygosity from 60% to 70%). All markers are also highly informative represented by Polymorphic Information Content (PIC) more than 0.5. Informativeness of panels also was evaluated. One hundred percent of samples had at least one heterozygous marker in panels of each 3 genes (*MYBPC3*, *TNNI3*, and *MYL2*). For the other 3 genes (*MYH7*, *TNNT2*, and *TPM1*) 96--98% of samples had at least one heterozygote marker in related panels. Two samples showed homozygosity for all 4 markers around one gene. One sample showed homozygosity for all markers around two genes (*MYH7* and *TNNT2*). Looking to their pedigrees, it was realized that these samples had consanguineous parents (first cousin). Offsprings of first cousins have autozygosity in 1/16 of their loci. Therefore finding homozygous haplotypes in these people is expected. The above findings were obviously independent from the Informativeness of the markers used. Therefore, we confidently suggest using these panels for future gene tracking experiments in our population.

In addition, multiplexing of PCRs for all 24 markers in only 3 reactions and 2 runs of capillary electrophoresis make our strategy very cost-effective. Not forgetting that the whole experimental process can be performed in only one day, this is a very short time in comparison with other available testing methods.

Using linkage strategy for mutation detection in familial HCM was performed before ([@B6], [@B17]--[@B19]). However, multiplexing was reported in only one study. Mogensen et al. reported multiplexing of 28 markers surrounding 9 genes in 10 reactions and 10 runs of capillary electrophoresis for fragment length analysis ([@B20]).

Applying the panel for the presented family with HCM showed the power of our strategy in exclusion of these 6 common HCM genes. This strategy was also successfully applied for gene tracking in a number of pedigrees with familial HCM (data was not shown.)

Conclusion
==========

Our study presented a fast, cost-effective and reliable method for diagnostic, predictive, or screening testing in familial HCM. It should not be forgotten that gene tracking is useful only for the familial forms of diseases. Suggested strategy cannot be used for genetic diagnosis in sporadic cases.
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